The University of Southampton
University of Southampton Institutional Repository

Can medication effects be determined using national registry data? A cautionary reflection on risk of bias in "big data" analytics; based on Chang et al., 2016.

Can medication effects be determined using national registry data? A cautionary reflection on risk of bias in "big data" analytics; based on Chang et al., 2016.
Can medication effects be determined using national registry data? A cautionary reflection on risk of bias in "big data" analytics; based on Chang et al., 2016.
Stimulant and non-stimulant medications are recommended as part of ADHD treatment, based on the best available evidence of their costs and benefits(1). At the same time, some important clinical questions remain to be definitively resolved. This is because of both limitations in the scope of prior trials and, in some cases, their methodological and design weaknesses. Added to this, a degree of scepticism exists, in some quarters, concerning the veracity of the ADHD medication evidence-base as a whole, because of the potentially distorting effect of pharmaceutical industry involvement in trials.
0006-3223
1-10
Sonuga-Barke, Edmund
bc80bf95-6cf9-4c76-a09d-eaaf0b717635
Sonuga-Barke, Edmund
bc80bf95-6cf9-4c76-a09d-eaaf0b717635

Sonuga-Barke, Edmund (2016) Can medication effects be determined using national registry data? A cautionary reflection on risk of bias in "big data" analytics; based on Chang et al., 2016. Biological Psychiatry, 1-10. (doi:10.1016/j.biopsych.2016.10.002).

Record type: Article

Abstract

Stimulant and non-stimulant medications are recommended as part of ADHD treatment, based on the best available evidence of their costs and benefits(1). At the same time, some important clinical questions remain to be definitively resolved. This is because of both limitations in the scope of prior trials and, in some cases, their methodological and design weaknesses. Added to this, a degree of scepticism exists, in some quarters, concerning the veracity of the ADHD medication evidence-base as a whole, because of the potentially distorting effect of pharmaceutical industry involvement in trials.

Text
__soton.ac.uk_ude_PersonalFiles_Users_bs1c06_mydocuments_EDMUND_papers and chapters_Biological Psychiatry commentary 30 Sept 16_Sonuga-Barke BPS commentary_final(ammended).docx - Accepted Manuscript
Download (30kB)

More information

Accepted/In Press date: 4 October 2016
e-pub ahead of print date: 6 October 2016
Organisations: Clinical Neuroscience

Identifiers

Local EPrints ID: 401297
URI: http://eprints.soton.ac.uk/id/eprint/401297
ISSN: 0006-3223
PURE UUID: a9bc369c-8d50-4a69-9bf7-04dc1a32a2e0

Catalogue record

Date deposited: 11 Oct 2016 15:31
Last modified: 15 Mar 2024 05:57

Export record

Altmetrics

Contributors

Author: Edmund Sonuga-Barke

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×